18 Antibody

What is the mechanism of action for COVA1-18 against SARS-CoV-2?

COVA1-18 is a highly potent neutralizing antibody that targets SARS-CoV-2, showing particular effectiveness against the B.1.1.7 isolate. Its mechanism involves binding to the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein with high affinity. The antibody's potency is dependent on avidity, with studies showing remarkably low IC50 values of 0.8 ng/ml (5.2 pM) against lentiviral SARS-CoV-2 pseudovirus and 9 ng/ml (60 pM) against VSV-based pseudovirus .

The binding characteristics of COVA1-18 have been determined using bio-layer interferometry, which revealed that the IgG version of this antibody has a stronger binding affinity to the SARS-CoV-2 RBD compared to the Fab version, highlighting the importance of avidity in its neutralizing activity .

How effective is COVA1-18 in various preclinical models?

COVA1-18 has demonstrated robust antiviral activity across three distinct preclinical models:

• hACE2 Transgenic Mice: In both prophylactic and therapeutic settings, SARS-CoV-2 remained undetectable in the lungs of treated mice. When administered at 10 mg/kg, the antibody provided complete protection .

• Syrian Hamsters: Therapeutic treatment with COVA1-18 resulted in significant reduction of viral loads in the lungs .

• Cynomolgus Macaques: When administered at 10 mg/kg one day prior to high-dose SARS-CoV-2 challenge, COVA1-18 showed very strong antiviral activity in the upper respiratory compartments. Mathematical modeling estimated that the antibody reduced viral infectivity by more than 95% in these compartments, preventing lymphopenia and extensive lung lesions .

These consistent results across different animal models suggest that COVA1-18 could be a valuable candidate for clinical evaluation in humans.

What are the methodological considerations for detecting COVA1-18 in biological samples?

Detecting COVA1-18 in biological samples requires specific methodologies:

• ELISA-Based Detection: Studies have adapted protocols to detect human IgG in non-human primate (NHP) fluid samples. This involves coating plates with goat anti-Human IgG H+L (monkey pre-adsorbed) antibodies, followed by blocking with casein buffer. Samples are serially diluted alongside COVA1-18 standards, and detection is achieved using goat anti-Human IgG (monkey adsorbed)-HRP secondary antibodies for serum samples or goat anti-Human IgG (monkey adsorbed)-BIOT followed by poly-HRP40 for mucosal samples .

• Concentration Determination: COVA1-18 concentration in specific samples is determined by interpolating optical density values from dilutions within the linear range of the standard curve on the matching ELISA plate .

• Sample Collection Timing: For optimal detection, researchers should consider the pharmacokinetics of COVA1-18, collecting samples at appropriate intervals after administration, particularly when studying its prophylactic or therapeutic effects.

What are the challenges in developing neutralizing antibodies against IL-18?

Developing effective neutralizing antibodies against IL-18 presents several challenges:

• Host Tolerance: Since IL-18 is an endogenous protein, conventional immunization approaches may not generate robust immune responses due to host tolerance. To overcome this, researchers have successfully used IL-18-deficient mice for immunization, as demonstrated in the production of isogenic monoclonal antibodies directed against murine IL-18 .

• Adjuvant Selection: Proper adjuvant selection is critical. Research has shown that using CpG-oligodeoxynucleotides (CpG-ODN) and alum as adjuvants can result in high anti-IL-18 serum titers in IL-18-deficient mice .

• Functional Testing: Identifying truly neutralizing antibodies requires rigorous functional testing. For example, antibody SK721-2 and SK113AE-4 were identified to bind IL-18 and neutralize its IFN-gamma inducing effect in vitro with an IC50 of 40-100 ng/ml .

How can researchers assess the specificity and cross-reactivity of anti-IL-18 antibodies?

Assessing specificity and cross-reactivity of anti-IL-18 antibodies requires multiple approaches:

• Bioassay Testing: An IL-18 bioassay can be employed to determine whether antibodies interfere with the regulatory effect of IL-18. For instance, research showed that antibody 441 did not interfere with the regulatory effect of murine IL-18BP, while other antibodies did .

• Biolayer Interferometry (BLI): This technique can characterize binding kinetics and dissociation constants. In one study, BLI was performed using an Octet Red 96 machine in specific buffer conditions (20 mM HEPES pH 7.4, 150 mM NaCl, 0.1% BSA, 0.05% Tween 20) at 25°C. Antibodies were biotinylated and immobilized onto Octet® SA capture biosensors until an optical shift of 2 nm was achieved .

• Cross-Reactivity Testing: Testing against related cytokines or in biological samples from different species is essential. The search results indicate that cross-reactivity testing panel should include related interleukins and samples from various inflammatory conditions to ensure specificity .

What methodological approaches are effective for studying IL-18 inhibition with antibodies?

Several methodological approaches have proven effective for studying IL-18 inhibition:

• Cell-Based Assays: Using stably transfected cell lines expressing IL-18 receptors (such as RAW 264.7 cells expressing mIL-18R) to test functional activity of anti-IL-18 antibodies .

• In Vitro Cytokine Production: Measuring IL-18-induced IFNγ, IL-6, and TNFα production in human cell lines and peripheral blood mononuclear cells (PBMCs) to assess inhibitory effects of anti-IL-18 antibodies .

• In Vivo Models: Using disease models such as Macrophage Activation Syndrome (MAS) induced by CpG oligonucleotide to evaluate the ability of anti-IL-18 antibodies to reduce pathology. In one study, IL-18BP KO and WT mice received 200 μg anti-IL-18BP antibody clones before CpG injection, with additional injections over several days .

• Whole Blood Cultures: Testing antibody inhibition of LPS-induced IFNγ production in whole blood cultures provides a more physiologically relevant assessment of antibody efficacy .

What techniques are most effective for determining antibody binding kinetics?

Several techniques are effective for determining antibody binding kinetics, with biolayer interferometry (BLI) being particularly valuable:

• Biolayer Interferometry: This technique provides real-time, label-free analysis of biomolecular interactions. For example, in characterizing anti-IL-18BP antibodies, researchers:

  • Biotinylated antibodies using NHS-PEG4 Biotinylation Kit

  • Immobilized them at 100 nM onto Octet® SA capture biosensors

  • Tested against various concentrations of target protein (12.5-100 nM)

  • Used 400s association phase followed by 1200s dissociation phase

  • Fitted data to a 1:1 global model after reference subtraction

  • Reported kinetic parameters (KD, ka, kd) as averages from technical replicates

• ELISA-Based Methods: While less precise for kinetics, these can provide valuable relative affinity information. Direct ELISAs in 384-microtiterplate format were developed to identify antibodies against mouse IL-18BP, which were used to screen B-cell supernatants .

• Functional Assays: IC50 determinations in functional assays provide important information on potency. For anti-IL-1R7 antibodies, researchers determined their ability to inhibit IL-18-induced signaling with EC50 values ranging from 40.3 ng/ml to 994 ng/ml depending on the antibody clone .

How should researchers approach antibody validation for research applications?

Comprehensive antibody validation requires multiple approaches:

• Multi-Method Confirmation: Using different methods to confirm specificity. For example, the Human Cytokeratin 18 Antibody (AF7619) was validated using Western blot, immunocytochemistry, and Simple Western techniques to confirm specific detection of cytokeratin 18 .

• Positive and Negative Controls: Including appropriate controls is critical. For Cytokeratin 18 detection, researchers used HeLa cells as positive controls and HeLa KRT18 Knockout cells as negative controls to confirm antibody specificity .

• Cross-Reactivity Testing: Testing against a panel of potentially cross-reactive targets. Data shows specificity testing should include:

  • Related protein family members (e.g., testing anti-Cytokeratin 18 against other cytokeratins)

  • Common infectious agents (EBV, coronaviruses, Mycoplasma pneumoniae)

  • Physiological conditions (pregnancy)

• Testing in Multiple Sample Types: Validating across different sample types (e.g., cell lines, tissue sections, serum) depending on intended applications .

What factors contribute to antibody cross-reactivity and how can it be mitigated?

Cross-reactivity remains a significant challenge in antibody research, with studies showing that up to one-third of antibody-based drugs exhibit nonspecific binding to unintended targets . Key factors and mitigation strategies include:

• Structural Similarity: Proteins with similar epitopes can lead to cross-reactivity. For example, serological tests for SARS-CoV-2 showed cross-reactivity with other coronaviruses (229E, OC43, NL63), EBV, and Mycoplasma pneumoniae .

• Mitigation Strategies:

  • Affinity Purification: Passing antibody-containing serum through a column with immobilized antigen allows specific binding and purification of target-specific antibodies .

  • Adsorption: Pre-adsorbing antibodies against potential cross-reactive antigens can improve specificity, as seen with monkey pre-adsorbed antibodies used in ELISA detection of human antibodies in NHP samples .

  • Advanced Screening Tools: The Membrane Proteome Array™ (MPA), a cell-based protein array representing the human membrane proteome, can test antibody specificity and improve safety by identifying off-target binding .

• Epitope Selection: Choosing unique epitopes for antibody development reduces cross-reactivity risk. Research has shown that targeting less conserved regions of proteins results in higher specificity .

How do different antibody detection platforms compare in sensitivity and specificity?

A comprehensive evaluation of 18 commercial serological assays for SARS-CoV-2 antibody detection revealed significant performance differences across platforms:

Key findings from comparative analyses include:

• Enzyme-Linked Immunosorbent Assays (ELISAs): Generally provided high sensitivity (88.0-96.0%) in late samples (>14 days), with varying specificity (68.2-100%). The Vircell IgG and Wantai Ig ELISAs consistently showed the highest sensitivity at 96.0% .

• Electrochemiluminescence Immunoassay (ECLIA): Roche Ig showed 88.0% sensitivity with 100% specificity .

• Point-of-Care Tests (POCTs): Performance varied considerably, with sensitivity ranging from 88.0% to 100% and specificity from 81.0% to 100%. The POCTs from Boson Biotech and VivaChek Laboratories showed the highest sensitivities (100%), while Orient Gene Biotech, VivaChek Laboratories, and VOMED Diagnostics showed 100% specificity .

• Timing Impact: For all platforms, performance was significantly better in samples collected >14 days after symptom onset compared to early samples (6-8 days) .

What methodological factors affect inter-laboratory variability in antibody testing?

Research on antibody testing standardization has identified several factors affecting inter-laboratory variability:

• Assay Type Differences: For plaque reduction neutralization tests (PBNA), inter-laboratory differences in absolute antibody concentrations showed geometric coefficients of variation (%GCVs) between 48-348%. For antibody-binding assays, variability was much greater, with %GCVs ranging from 606% to 3923% .

• Technical Performance Metrics:

  • Within-assay agreement for duplicate samples typically showed acceptable intra-assay variability, with most laboratory estimates within a 20% difference

  • Inter-assay variation across independent assays was generally acceptable, with 97.0% of PBNA and 98.9% of Ab-binding assays showing no more than 4-fold spread between maximum and minimum estimates

• Maximum:Minimum Differences: The differences between maximum and minimum titers across laboratories for PBNA ranged from 3.1 to 78.2-fold, while Ab-binding assays showed much greater variability with differences ranging from 115 to 12800-fold .

• Standardization Need: The extreme variability in Ab-binding assays reflects the use of laboratory-defined units that are not equivalent, making it impossible to compare results across laboratories without standardization efforts .

How does disease severity affect antibody detection performance?

Disease severity significantly impacts antibody detection across all testing platforms:

• Sensitivity Correlation with Severity: For all antibody tests evaluated, sensitivity was markedly higher in sera from patients with severe disease compared to those with mild to moderate disease. In patients with severe disease (ICU patients), sensitivity of most tests for >14 days sera was 100%, while sensitivity was consistently lower in healthcare workers with mild to moderate symptoms .

• Quantitative Data from Comparative Study:

What are the considerations for developing CH14.18/CHO antibodies for therapeutic applications?

The development of ch14.18/CHO antibodies for therapeutic applications involves several important considerations:

• Production System Changes: Transitioning from murine cell lines to CHO cells can help avoid murine xenotropic retrovirus contamination while maintaining identical protein sequences by using the same plasmid employed in earlier clinical trials .

• Regulatory Requirements: The European Medicines Agency (EMA) guidelines require a Phase 1 bridging study to assess the safety, pharmacokinetic, and activity profiles of recloned antibodies like ch14.18/CHO .

• Functional Validation: Before clinical testing, ch14.18/CHO antibodies should be demonstrated to mediate antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) as effectively as the original antibody controls .

• Preclinical Models: Testing in appropriate preclinical models, such as neuroblastoma models for ch14.18/CHO, is essential to demonstrate efficacy in suppressing experimental metastasis .

How can researchers optimize antibody-based immunoassays for maximum reliability?

Optimizing antibody-based immunoassays requires attention to several key factors:

• Secondary Antibody Selection: The choice of secondary antibody is crucial and should consider:

  • Target species compatibility (the species from which the primary antibody was derived)

  • Target immunoglobulin class or subclass specificity

  • Whether the secondary antibody binds to a particular part of the antibody

  • Appropriate conjugation (e.g., HRP, fluorescent dyes) for the detection method

• Assay Standardization: To reduce variability, researchers should:

  • Include proper reference standards with known antibody concentrations

  • Perform multiple independent assay runs (at least 3)

  • Include duplicate samples to assess intra-assay variation

  • Calculate and report geometric coefficients of variation (%GCVs)

• Timing Considerations: For serological assays, timing of sample collection is critical. Research has shown that antibody detection sensitivity is significantly higher in samples collected >14 days after symptom onset compared to early samples .

• Cross-Reactivity Testing: Include appropriate controls to detect potential cross-reactivity with:

  • Other coronaviruses for SARS-CoV-2 antibody assays

  • EBV and Mycoplasma pneumoniae samples

  • Pregnancy samples

What emerging technologies are improving antibody specificity assessment?

Several emerging technologies are enhancing our ability to assess antibody specificity:

• Membrane Proteome Array™ (MPA): This cell-based protein array represents the human membrane proteome and allows comprehensive testing of antibody specificity against potential off-target proteins. Research has shown that up to one-third of antibody-based drugs exhibit nonspecific binding to unintended targets, and the MPA can identify these issues early in development .

• Advanced Computational Analysis: Computational methods to predict potential cross-reactivity based on epitope structure and protein homology are improving the design of more specific antibodies .

• Knockout Cell Line Validation: The use of knockout cell lines as negative controls provides definitive validation of antibody specificity. For example, Human Cytokeratin 18 Antibody was validated using HeLa KRT18 Knockout cells as a negative control compared to wild-type HeLa cells .

• International Standardization Efforts: Collaborative studies establishing International Standards (ISs) for antibodies, such as those for HPV antibodies, are creating reference materials that can significantly improve inter-laboratory comparability of antibody measurements .

These emerging technologies and approaches are addressing the significant concern of off-target binding, which has been identified as a major cause of drug attrition and adverse events in patients .